Gilead secures new anti-cancer therapy in $4.9bn deal
02-03-2020
Sundry Photography / Shutterstock.com
Gilead Sciences has unveiled an agreement with Jounce Therapeutics to exclusively develop and license its antibody programme, JTX-1811, which is designed to fight cancer cells.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead, Jounce Therapeutics, cancer treatment, JTX-1811, agreement, equity investment, IND, tumours, immunotherapy, antitrust, royalties, oncology
